Generic placeholder image

Current Applied Polymer Science

Editor-in-Chief

ISSN (Print): 2452-2716
ISSN (Online): 2452-2724

Review Article

Essential Polymers Helping Patients with Obesity

Author(s): Maria Nascimento, Kaushik Pal and Fernando Gomes*

Volume 4, Issue 2, 2021

Published on: 04 January, 2021

Page: [99 - 106] Pages: 8

DOI: 10.2174/2452271604999210104222642

Price: $65

Abstract

Background: In the last decades, the prevalence of obesity showed a significant increase in several countries. This fact is very worrying since there is an association between obesity and metabolic alterations, such as type II diabetes, hypertension, cardiovascular diseases, some types of cancer, and glucose intolerance. Knowledge of causes, preventive strategies, and treatment have been objects of studies by researchers in several centers.

Objective: The present paper aims to review some studies addressing the increase in the prevalence and incidence of obesity, diseases related to overweight, and procedures to reduce body fat. The primary focus of the presented work is the use of polymer systems as an alternative to the conventional pharmacological treatment of obesity, exploiting the natural and synthetic polymer systems that have excellent efficiency and can promote improvement to the existing therapies.

Results: The use of polymers presents the growing relevance as a new therapy and to the improvement of existing treatments. Among the polymers studied in the treatment of obesity, natural polymers such as chitosan and alginate have gained prominence. Synthetic polymer systems such as poly (ε-caprolactone) and poly (lactide-co-glycolide) were also studied for the treatment of obesity.

Conclusion: This mini-review reflects exclusive strategies that point out to polymers that can be an alternative to conventional pharmacological treatments or even as occupants in the treatment of obesity. Besides, we do believe that the most profound union between Polymers and Medical Science will allow us to mitigate this disease and all associated conditions, improving the quality of life, mainly of the poor populations from emerging countries.

Keywords: Obesity, treatment, natural polymer, synthetic polymer, DDS, therapies.

Graphical Abstract
[1]
Alipoor E, Hosseinzadeh-Attar MJ, Rezaei M, Jazayeri S, Chapman M. White adipose tissue browning in critical illness: A review of the evidence, mechanisms and future perspectives. Obes Rev 2020; 21(12): e13085.
[http://dx.doi.org/10.1111/obr.13085] [PMID: 32608573]
[2]
Alsubhi M, Goldthorpe J, Epton T, Khanom S, Peters S. What factors are associated with obesity-related health behaviours among child refugees following resettlement in developed countries? A systematic review and synthesis of qualitative and quantitative evidence. Obes Rev 2020; 21(11): e13058.
[http://dx.doi.org/10.1111/obr.13058] [PMID: 32608177]
[3]
Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019; 92: 170-92.
[http://dx.doi.org/10.1016/j.metabol.2018.10.010] [PMID: 30391259]
[4]
Umashanker D, Igel LI, Kumar RB, Aronne LJ. Current and future medical treatment of obesity. Gastrointest Endosc Clin N Am 2017; 27(2): 181-90.
[http://dx.doi.org/10.1016/j.giec.2016.12.008] [PMID: 28292399]
[5]
Donninelli G, Del Cornò M, Pierdominici M, et al. Distinct blood and visceral adipose tissue regulatory T cell and innate lymphocyte profiles characterize obesity and colorectal cancer. Front Immunol 2017; 8: 643.
[http://dx.doi.org/10.3389/fimmu.2017.00643] [PMID: 28649243]
[6]
Muanprasat C, Chatsudthipong V. Chitosan oligosaccharide: Biological activities and potential therapeutic applications. Pharmacol Ther 2017; 170: 80-97.
[http://dx.doi.org/10.1016/j.pharmthera.2016.10.013] [PMID: 27773783]
[7]
Valsamakis G, Konstantakou P, Mastorakos G. New targets for drug treatment of obesity. Annu Rev Pharmacol Toxicol 2017; 57: 585-605.
[http://dx.doi.org/10.1146/annurev-pharmtox-010716-104735] [PMID: 28061687]
[8]
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53(21): 1925-32.
[http://dx.doi.org/10.1016/j.jacc.2008.12.068] [PMID: 19460605]
[9]
Lainas P, De Filippo G, Di Giuro G, Mikhael R, Bougneres P, Dagher I. Laparoscopic sleeve gastrectomy for adolescents under 18 years old with severe obesity. Obes Surg 2020; 30(1): 267-73.
[http://dx.doi.org/10.1007/s11695-019-04150-6] [PMID: 31520302]
[10]
Rychter AM, Zawada A, Ratajczak AE, Dobrowolska A, Krela-Kaźmierczak I. Should patients with obesity be more afraid of COVID-19? Obes Rev 2020; 21(9): e13083.
[http://dx.doi.org/10.1111/obr.13083] [PMID: 32583537]
[11]
Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes 2020; 10(3): e12365.
[http://dx.doi.org/10.1111/cob.12365] [PMID: 32342637]
[12]
Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020; 43(7): 1392-8.
[http://dx.doi.org/10.2337/dc20-0576] [PMID: 32409502]
[13]
Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring) 2020; 28(6): 1005-5.
[http://dx.doi.org/10.1002/oby.22818] [PMID: 32237206]
[14]
Lighter J, Phillips M, Hochman S, et al. Stachel, A Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020; 71(15): 896-7.
[http://dx.doi.org/10.1093/cid/ciaa415] [PMID: 32271368]
[15]
Post A, Bakker SJ, Dullaart RP. Obesity, adipokines and COVID-19. Eur J Clin Invest 2020; 50: e13313.
[http://dx.doi.org/10.1111%2Feci.13313] [PMID: 32531806]
[16]
Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev 2020; 21(6): e13034.
[http://dx.doi.org/10.1111/obr.13034] [PMID: 32281287]
[17]
Kim JD, Diano S. A sympathetic treatment for obesity. Cell Metab 2020; 31(6): 1043-5.
[http://dx.doi.org/10.1016/j.cmet.2020.05.009] [PMID: 32492388]
[18]
Xia Q, Campbell JA, Ahmad H, Si L, de Graaff B, Palmer AJ. Bariatric surgery is a cost-saving treatment for obesity-A comprehensive meta-analysis and updated systematic review of health economic evaluations of bariatric surgery. Obes Rev 2020; 21(1): e12932.
[http://dx.doi.org/10.1111/obr.12932] [PMID: 31733033]
[19]
Joyce P, Meola TR, Schultz HB, Prestidge CA. Biomaterials that regulate fat digestion for the treatment of obesity. Trends Food Sci Technol 2020; 100: 235-45.
[http://dx.doi.org/10.1016/j.tifs.2020.04.011]
[20]
Gasmi A, Mujawdiya PK, Shanaida M, et al. Calanus oil in the treatment of obesity-related low-grade inflammation, insulin resistance, and atherosclerosis. Appl Microbiol Biotechnol 2020; 104(3): 967-79.
[http://dx.doi.org/10.1007/s00253-019-10293-4] [PMID: 31853565]
[21]
Bhandari M, Jain S, Mathur W, et al. Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience. Dig Endosc 2020; 32(4): 541-6.
[http://dx.doi.org/10.1111/den.13508] [PMID: 31394006]
[22]
Killion EA, Lu S-C, Fort M, Yamada Y, Véniant MM, Lloyd DJ. Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists= antagonists? Endocr Rev 2020; 41(1): 1-21.
[http://dx.doi.org/10.1210/endrev/bnz002] [PMID: 31511854]
[23]
Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol 2020; 75(2): 235-51.
[http://dx.doi.org/10.1037/amp0000517] [PMID: 32052997]
[24]
Bielawiec P, Harasim-Symbor E, Chabowski A. Phytocannabinoids: Useful drugs for the treatment of obesity? Special focus on cannabidiol. Front Endocrinol (Lausanne) 2020; 11: 114.
[http://dx.doi.org/10.3389/fendo.2020.00114] [PMID: 32194509]
[25]
Heffron SP, Parham JS, Pendse J, Alemán JO. Treatment of obesity in mitigating metabolic risk. Circ Res 2020; 126(11): 1646-65.
[http://dx.doi.org/10.1161/CIRCRESAHA.119.315897] [PMID: 32437303]
[26]
Kakazu MT, Soghier I, Afshar M, et al. Weight loss interventions as treatment of obesity hypoventilation syndrome. A systematic review. Ann Am Thorac Soc 2020; 17(4): 492-502.
[http://dx.doi.org/10.1513/AnnalsATS.201907-554OC] [PMID: 31978317]
[27]
Spindola KC, Simas NK, Santos CE dos, et al. Dendranthema grandiflorum, a hybrid ornamental plant, is a source of larvicidal compounds against Aedes aegypti larvae. Rev Bras Farmacogn 2016; 26(3): 342-6.
[http://dx.doi.org/10.1016/j.bjp.2016.01.003]
[28]
de Araújo Segura TC, Pereira ED, Icart LP, Fernandes E, Esperandio de Oliveira G, de Souza Jr FG. Hyperthermic agent prepared by one-pot modification of maghemite using an aliphatic polyester model. Polym Sci Ser B 2018; 60(6): 806-15.
[http://dx.doi.org/10.1134/S1560090418060106]
[29]
Pereira ED, Souza FG, Santana CI, Soares DQ, Lemos AS, Menezes LR. Influence of magnetic field on the dissolution profile of cotrimoxazole inserted into poly(lactic acid-co-glycolic acid) and maghemite nanocomposites. Polym Eng Sci 2013; 53(11): 2308-17.
[http://dx.doi.org/10.1002/pen.23606]
[30]
Pereira ED, Cerruti R, Fernandes E, et al. Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin. Polímeros 2016; 26(2): 137-43.
[http://dx.doi.org/10.1590/0104-1428.2323]
[31]
Lange J, Souza FG Jr, Nele M, Tavares FW, Segtovich ISV, da Silva GCQ. Molecular dynamic simulation of oxaliplatin diffusion in poly(lactic acid-co-glycolic acid). Part A: Parameterization and validation of the force-field CVFF. Macromol Theory Simul 2015; 25(1): 45-62.
[http://dx.doi.org/10.1002/MATS.201500049]
[32]
Icart LP, Santos EFD, Luztonó L. Paclitaxel-loaded PLA/PEG/magnetite anticancer and hyperthermic agent prepared from materials obtained by the Ugi’s multicomponent reaction. Macromol Symp 2018; 380(1): 1800094.
[http://dx.doi.org/10.1002/masy.201800094]
[33]
Icart L, Souza FGJr, Ramón J. PLA-b-PEG/magnetite hyperthermic agent prepared by ugi four component condensation. Express Polym Lett 2016; 10(3): 188-203.
[http://dx.doi.org/10.3144/expresspolymlett.2016.18]
[34]
Besteti MD, Souza FG Jr, Freire DMG, Pinto JC. Production of core-shell polymer particles-containing cardanol by semibatch combined suspension/emulsion polymerization. Polym Eng Sci 2014; 54(5): 1222-9.
[http://dx.doi.org/10.1002/pen.23660]
[35]
Saez V, Cerruti R, Ramón JA, Fernandes E. Quantification of oxaliplatin encapsulated into PLGA microspheres by TGA. Macromol Symp 2016; 368: 116-21.
[http://dx.doi.org/10.1002/masy.201500181]
[36]
Icart LP, Souza FG, Lima LM. Sustained release and pharmacologic effects of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. bioRxiv 2019; 36(8): 747-58.
[http://dx.doi.org/10.1080/02652048.2019.1677795] [PMID: 31594428]
[37]
Mohamed GA, Ibrahim SRM, Elkhayat ES, El Dine RS. Natural anti-obesity agents. Bull Fac Pharm Cairo Univ 2014; 52(2): 269-84.
[http://dx.doi.org/10.1016/j.bfopcu.2014.05.001]
[38]
Gallo M, Naviglio D, Armone Caruso A, Ferrara L. 13 - Applications of chitosan as a functional food. In Grumezescu AM, Ed. Novel Approaches of Nanotechnology in Food Nanotechnology in the Agri-Food Industry, Vol 1. US: Elsevier, Academic Press 2016; pp. 425-64.
[39]
Bauer EM, Ben-Artzi A, Duffy EL, et al. Joint-specific assessment of swelling and power doppler in obese rheumatoid arthritis patients. BMC Musculoskelet Disord 2017; 18(1): 99.
[http://dx.doi.org/10.1186/s12891-017-1406-7] [PMID: 28259162]
[40]
Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med 2016; 129(8): 879.e1-6.
[http://dx.doi.org/10.1016/j.amjmed.2016.02.009] [PMID: 26949003]
[41]
Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012; 37(1): 106-26.
[http://dx.doi.org/10.1016/j.progpolymsci.2011.06.003] [PMID: 22125349]
[42]
Nurdiantami Y, Watanabe K, Tanaka E, Pradono J, Anme T. Association of general and central obesity with hypertension. Clin Nutr 2018; 37(4): 1259-63.
[http://dx.doi.org/10.1016/j.clnu.2017.05.012] [PMID: 28583324]
[43]
Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes 2018; 42(3): 495-500.
[http://dx.doi.org/10.1038/ijo.2017.287] [PMID: 29151591]
[44]
Reynés B, Serrano A, Petrov PD, et al. Anti-obesity and insulin-sensitising effects of a glycosaminoglycan mix. J Funct Foods 2016; 26: 350-62.
[http://dx.doi.org/10.1016/j.jff.2016.07.022]
[45]
Kushner RF, Herrington H. Surgery for severe obesity. In: Coulston AM, Boushey CJ, Ferruzzi MG, Delahanty LM, Eds. Nutrition in the prevention and treatment of disease. 3rd ed.. US: Academic Press 2017; pp. 499-514.
[46]
Ryan DH, Herrington H. Guidelines for obesity management. Endocrinol Metab Clin 2016; 45(3): 501-10.
[http://dx.doi.org/10.1016/j.ecl.2016.04.003]
[47]
Mathieu P, Boulanger M-C, Després JP. Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk. Rev Endocr Metab Disord 2014; 15(4): 289-98.
[http://dx.doi.org/10.1007/s11154-014-9299-3] [PMID: 25326657]
[48]
Almeida MA, Nadal JM, Grassiolli S, et al. Enhanced gastric tolerability and improved anti-obesity effect of capsaicinoids-loaded PCL microparticles. Mater Sci Eng C 2014; 40: 345-56.
[http://dx.doi.org/10.1016/j.msec.2014.03.049] [PMID: 24857502]
[49]
Oestreich AK, Moley KH. Developmental and transmittable origins of obesity-associated health disorders. Trends Genet 2017; 33(6): 399-407.
[http://dx.doi.org/10.1016/j.tig.2017.03.008] [PMID: 28438343]
[50]
Revels S, Kumar SAP, Ben-Assuli O. Predicting obesity rate and obesity-related healthcare costs using data analytics. Health Policy Technol 2017; 6(2): 198-207.
[http://dx.doi.org/10.1016/j.hlpt.2017.02.002]
[51]
Acosta A, Camilleri M. A working paradigm for the treatment of obesity in gastrointestinal practice. Tech Gastrointest Endosc 2017; 19(1): 52-60.
[http://dx.doi.org/10.1016/j.tgie.2017.01.003] [PMID: 28936110]
[52]
Yuan D, Yi X, Zhao Y, et al. Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. J Control Release 2017; 263: 172-84.
[http://dx.doi.org/10.1016/j.jconrel.2017.03.029] [PMID: 28344017]
[53]
Kurisu S, Ikenaga H, Watanabe N, et al. Electrocardiographic characteristics in the underweight and obese in accordance with the World Health Organization classification. IJC Metab Endocr 2015; 9: 61-5.
[http://dx.doi.org/10.1016/j.ijcme.2015.10.006]
[54]
Gómez-Hernández A, Beneit N, Díaz-Castroverde S, Escribano O. Differential role of adipose tissues in obesity and related metabolic and vascular complications. Int J Endocrinol 2016; 2016: 1216783. https://www.hindawi.com/journals/ije/2016/1216783/
[55]
Herrera RMA, Fernández-García JM, Andújar CR, Altozano SC, Carpi UJJ. Tratamiento farmacológico de la obesidad para médicos de Atención Primaria Pharmacological treatment of obesity for primary care physicians. Med Fam SEMERGEN 2019; 45(8): 559-65.
[http://dx.doi.org/10.1016/j.semerg.2019.04.005]
[56]
Wasinski F, Frank RPB, Rufino GE. Exercise during pregnancy protects adult mouse offspring from diet-induced obesity. Nutr Metab (Lond) 2015; 12(56): 61-5. https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-015-0052-z
[57]
Wilcox MD, Brownlee IA, Richardson JC, Dettmar PW, Pearson JP. The modulation of pancreatic lipase activity by alginates. Food Chem 2014; 146: 479-84.
[http://dx.doi.org/10.1016/j.foodchem.2013.09.075] [PMID: 24176371]
[58]
Jiang C, Cano-Vega MA, Yue F, et al. Dibenzazepine-loaded nanoparticles induce local browning of white adipose tissue to counteract obesity. Mol Ther 2017; 25(7): 1718-29.
[http://dx.doi.org/10.1016/j.ymthe.2017.05.020] [PMID: 28624262]
[59]
He M, Zeng J, Zhai L, et al. Effect of in vitro simulated gastrointestinal digestion on polyphenol and polysaccharide content and their biological activities among 22 fruit juices. Food Res Int 2017; 102: 156-62.
[http://dx.doi.org/10.1016/j.foodres.2017.10.001] [PMID: 29195935]
[60]
Zhao X-H, Lin Y. Resistant starch prepared from high-amylose maize starch with citric acid hydrolysis and its simulated fermentation in vitro. Eur Food Res Technol 2009; 228: 1015-21.
[http://dx.doi.org/10.1007/s00217-009-1012-5]
[61]
Qi J, Li Y, Yokoyama W, et al. Cellulosic fraction of rice bran fibre alters the conformation and inhibits the activity of porcine pancreatic lipase. J Funct Foods 2015; 19: 39-48.
[http://dx.doi.org/10.1016/j.jff.2015.09.012]
[62]
Yi X, Kabanov AV. Brain delivery of proteins via their fatty acid and block copolymer modifications. J Drug Target 2013; 21(10): 940-55.
[http://dx.doi.org/10.3109/1061186X.2013.847098] [PMID: 24160902]
[63]
Paulus A, van Marken Lichtenbelt W, Mottaghy FM, Bauwens M. Brown adipose tissue and lipid metabolism imaging. Methods 2017; 130: 105-13.
[http://dx.doi.org/10.1016/j.ymeth.2017.05.001] [PMID: 28529065]
[64]
Zaia J, Li X-Q, Chan S-Y, Costello CE. Tandem mass spectrometric strategies for determination of sulfation positions and uronic acid epimerization in chondroitin sulfate oligosaccharides. J Am Soc Mass Spectrom 2003; 14(11): 1270-81.
[http://dx.doi.org/10.1016/S1044-0305(03)00541-5] [PMID: 14597117]
[65]
Zhang X-Z, Guan J, Cai S-L, Du Q. Guo, M-L Polymeric in situ hydrogel implant of epigallocatechin gallate (EGCG) for prolonged and improved antihyperlipidemic and anti-obesity activity: Preparation and characterization. J Biomater Tissue Eng 2015; 5(10): 813-7.
[http://dx.doi.org/10.1166/jbt.2015.1381]
[66]
Hsu W-H, Chang H-M, Lee Y-L, et al. Biodegradable polymer- nanoclay composites as intestinal sleeve implants installed in digestive tract for obesity and type 2 diabetes treatment. Mater Sci Eng C 2020; 110: 110676.
[http://dx.doi.org/10.1016/j.msec.2020.110676] [PMID: 32204104]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy